# IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

> **NCT01314118** · PHASE2 · COMPLETED · sponsor: **Janssen Biotech, Inc.** · enrollment: 131 (actual)

## Conditions studied

- Prostate Cancer
- Prostatic Neoplasm

## Interventions

- **DRUG:** abiraterone acetate in combination with prednisone

## Key facts

- **NCT ID:** NCT01314118
- **Lead sponsor:** Janssen Biotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05-04
- **Primary completion:** 2013-12-24
- **Final completion:** 2024-12-02
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01314118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01314118, "IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01314118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*